Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Misc Chemotherapy > Flashcards

Misc Chemotherapy Flashcards

1
Q

L-asparaginase:
MOA
use
A/E

A

MOA - breaks asparaginase
Use- ALL(VPAD)
A/E - Hyperglycemia, Hyperlipidemia, Hypercoagulation, Haemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Proteasome inhibitors

  • drugs
  • use
  • a/e
A

Bortezomib , Carflizomib
use- Multiple myeloma
A/E - thrombcytopenia , Peripheral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Denileukin diftitox

  • MOA
  • use
A

IL-2 causes death of CD-8

use - Cutaneous T-cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Gemtuzumab Ozagamycin
MOA
-use

A

Anti CD-33 mab

use - CD-33 AML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Brentuximab vedotin

  • MOA
  • use
A

MOA- anti CD-30

use - resistant CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inotuzumab Ozagamycin

  • MOA
  • use
A

MOA - anti - CD-22

use - resistant ALL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Moxetumomab pasudotox

  • MOA
  • use
A

MOA- Anti CD22 , pseudomonas toxin

use - resistant HCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tagraxofusp

  • MOA
  • Use
A
  • MOA - IL3

- Use - blastic plasmacytoid Dendritic cell neoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Polatuzumab vedotin

  • MOA
  • Use
A

anti CD79

use - DLBCL, along with Bendamustine, Rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CDK 4,6 Inhibitor

  • drugs
  • MOA
  • Use
A

Palbociclib, Rivociclib, Bemaciclib

  • MOA - inhibits G1 to S phase
  • Use - ER+ breast cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pembrolizumab

  • drugs
  • MOA
  • Use
A

/Nivolumab
moa - PD1 *R inhib
use - BRAF+ Malignant melanoma, Lynch syndrome, gastric cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ipilimumab

  • drugs
  • MOA
  • Use
A

/Premelimumab
CTLA4 *R inhib
use - Malignant melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Atezolimumab

  • MOA
  • Use
A

PD1 inhib

use - Urothelial CA, Non small cell CA, Triple neg breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Durvalumab

  • drugs
  • MOA
  • Use
A

/Avelumab
PD1 inhib
use - Merkel cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cemiplimab

  • MOA
  • Use
A

PD1 inhib

Squamous cell CA skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Venetoclax

  • MOA
  • Use
A

BCL2 inhib

use - CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Rucaparib

  • drugs
  • MOA
  • Use
A

/Olaparib, Niraparib - Rx Cisplatin resistant Fallopian tube , Ovarian and peritoneal CA, BRCA+ Breast cancer
/Talazoparib - BRCA+ Breast cancer
PARP inhib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Aldesleukin

  • MOA
  • use
A

IL2 analog

Malignant melanoma, RCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Sonic Hedgehog pathway inhib
drugs
use

A

/Vismodegib, Sonidegib - BCC

/Glasdegib- AML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Erlotinib

  • drugs
  • MOA
  • use
A

/Gefitinib > Osimertinib, Dacomatinib, Afatinib

  • TK - on EGFR
  • Non small carcinoma lung
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cetuximab

  • drugs
  • MOA
  • use
A

/Panitumumab - Head and neck cancer, colon cancer.
/Mecitumumab - Non small cell carcinoma lung
-EGFR inhib mab/ HER1 inhib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Lapatinib

  • drugs
  • MOA
  • use
A

/Neratinib
TK inhib on HER2
use- Trastuzumab refractory breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Trastuzumab

  • drugs
  • MOA
  • use
  • a/e
A

/Pertuzumab
HER2 inhib mab
HER2+ breast cancer, gastric cancer
a/e - cardiotoxicity

24
Q

Sunitinib

  • MOA
  • use
  • drugs
A

TK inhib of VEGF

  • DOC: RCC
  • GIST , pancreatic cancer

Sorafenib - DOC:HCC
Axitinib - RCC
Pazopanib - Soft tissue sarcoma
Vandetanib - multi TK- of VEGF, used in MedTC

25
Q

Ramucirumab

  • MOA
  • use
A

VEGF*R inhib

-Colon cancer, Gastric cancer, HCC

26
Q

Bevacizumab

  • MOA
  • use
  • a/e
A

VEGF inhib
RCC, diabetic retinopathy, Macular degeneration
a/e- Hypertension

27
Q

Ranibizumab

  • drugs
  • MOA
  • use
A

/Afilbercept, Brolucizumab
VEGF inhib
Macular degeneration

28
Q

Imatinib

  • MOA
  • use
A 
BCR-ABL TK inhib
-DOC: CML - 
2nd Gen- Bosutinib, Dasatinib, Nilotinib
T315 I mutation- INF alpha
3rd gen- Ponatinib

-DOC: GIST
>Sunitinib >Regorafenib >Ripretinib

-also used in Dermatofibrosarcoma, Hypereosionophilia syndrome

29
Q

Omacetaxime

  • MOA
  • use
  • a/e
A

inhib synthesis of BCR-ABL
use- multi TK- resistant CML
a/e - Hepatotoxicity, prolonged QT

30
Q

Ibrutinib

  • drugs
  • MOA
  • use
A

/Acalabrutinib (Ibrutinib resistant CLL)
Bruton TK-
use- CLL, Waldenstrom macroglobulinemia, Mantle cell lymphoma, Marginal cell lymphoma

31
Q

ALK inhib

  • drugs
  • use
A

1st gen- Crizotinib
2nd gen- Alcetinib, Brigatinib, Ceritinib
3rd gen - Lorlatinib

use- Non small CA lung

32
Q

FLT-3 inhib

  • drugs
  • use
A

/Midostaurin - AML, Mastocytosis, Mast cell CA

/Gilteritinib - AML

33
Q

Sipleucel-T

  • MOA
  • use
A
  • induce immune response against prostatic acid phosphatase

- 1st vaccine approved for cancer treatment

34
Q

Tisagenlecleucel

use

A

1st gene based therapy for ALL

35
Q

BRAF inhib

  • drugs
  • use
A

/Vemurafenib, Dabrafenib, Encokafenib

use- Malignant melanoma

36
Q

MEK inhib

  • drugs
  • use
A

/Tramatinib, Binimetinib, Cobimetinib

use - Malignant melanoma

37
Q

PIK-3 inhib
drugs
use

A

/Idelalisib, Duvalisib - CLL,NHL,SLL

/Alpelisib - ER+ Breast Cancer

38
Q

COVID mab

A

Casirivimab + Imdevimab

39
Q

Basiliximab
MOA
use

A

IL2 inhib , anti CD25

-Prevent transplant rejection

40
Q

Osteoporosis

A

Denosumab

41
Q

anti-RSV mab

A

Palivizumab

42
Q

Anti CD20 mab

  • drugs
  • use
A

/Rituximab - CLL, NHL, RA, SLE, TTP, ITP
/Ofatumumab, Obinutizumab - Rituximab resistant CLL
/Ocrelizumab - RA, Multiple Sclerosis

43
Q

PDGFR-

use

A

/Olaratumab

use - soft tissue sarcoma

44
Q

Dinutixumab

A

Mab against glycolipid GD2

Used for neuroblastoma

45
Q

Alemtuzumab

  • MOA
  • use
A
  • anti CD52

- Large cell lymphoma, Multiple Sclerosis

46
Q

mab against Bacillus anthracis

A

Obiltoxaximab

47
Q

Belimumab

  • MOA
  • use
A

Anti B-lymphocyte

-SLE

48
Q

Blinatumumab

-MOA

A

BITE mab- bi specific T cell engager

49
Q

Anti - Integrin mab

  • drugs
  • use
A

Vedolizumab - Crohn’s

Natalizumab - Multiple Sclerosis

50
Q

Omalizumab

A

-anti-IgE

asthma

51
Q

Reslizumab /

A

/Mepolizumab
IL-5 antagonist
asthma

52
Q

Muromonab

A

anti CD3

Acute organ rejection

53
Q

Efalizumab

A

anti CD11a

Psoriasis

54
Q

Itolizumab

A

anti CD6

Psoriasis

55
Q

Ustekinumab
MOA
Use

A

MOA - IgG1 man against IL-12/ IL-23

use- ulcerative colitis and Crohn’s disease

56
Q

Secukinumab
MOA
use

A

Anti IL17

ankylosis spondylitis

57
Q

Erdafitinib

A

Inhib of FGFR3 or 2

For metastatic urothelial cancer

Pharmacology (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions